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Abstract. Anaesthetics have been implicated to influence 
cancer cells and progression. Similarly, crosstalk between 
cancer cells and stromal components within the microen‑
vironment is also an important factor driving progression. 
Stromal cell‑derived factor‑1 (SDF‑1) and hepatocyte growth 
factor (HGF) are key chemokines/cytokines produced by 
fibroblasts which have been established as influential factors in 
cancer progression. The present study explored the capacity of 
anaesthetics to influence the expression of these key molecules 
in fibroblasts. The anaesthetics rocuronium bromide (RB), 
vecuronium bromide (VB), suxamethonium chloride 
CRS (SCC), dexmedetomidine hydrochloride (DH) and 
lidocaine were used to treat MRC‑5 fibroblasts over a range 
of concentrations. Following treatment, transcript expression 
of SDF‑1 and HGF was quantified using quantitative PCR. 
Treatment of MRC‑5 cells with RB brought about a reduction 
of SDF‑1 expression which was found to be significant in the 
45 µg/ml treatment group. Treatment with the other anaes‑
thetics brought about some alterations in SDF‑1 expression but 
these were not found to be statistically significant. Treatment 
with the tested anaesthetics did not have any significant effect 
on HGF transcript expression within MRC‑5 cells, although 
again some alterations were observed. The results indicated 
that anaesthetics may have an impact on the fibroblast compo‑
nent of the tumour microenvironment, potentially influencing 
SDF‑1 and HGF expression which in turn could influence 
tumour progression.
Introduction
Surgery is the most commonly used treatment for the majority 
of solid tumours. However, there is a growing recognition that 
surgery could potentially influence tumour recurrence and 
spread because of its effect on the immune system, the micro‑
environment or as a direct effect on cancer cells (1). Some 
retrospective studies have demonstrated that anaesthetic drugs 
have an impact, probably as one of multiple factors, on tumour 
proliferation and metastasis (1,2). Some studies have shown 
that anaesthetics played a role in promoting cancer metastasis, 
whilst others demonstrate that anaesthetics could induce 
apoptosis and reduce cancer recurrence and metastasis (1,3,4). 
However, a comprehensive understanding of the underlying 
mechanisms is still unclear.
The tumour microenvironment (TME), containing blood 
vessels, stroma cells and the extracellular matrix (ECM), plays 
a key role in cancer progression and metastasis (5). Fibroblasts, 
as one of the important components in the TME, play a vital 
role in tumour progression and metastasis (6). Fibroblasts, 
considered to be indolent in ECM in normal tissues become 
activated in response to wound healing, inflammation, or tissue 
damage caused by cancer cells (5). After that, stimuli including 
chemokines, cytokines, growth factors and exosomes released 
by fibroblasts can affect the TME by mediating immune cells, 
self‑sustained activation and regulating cancer cells (5,7). 
Stromal cell‑derived factor‑1 (SDF‑1) and hepatocyte growth 
factor (HGF) are key chemokines and cytokines derived 
from fibroblasts. They are known to promote tumourigenesis, 
metastasis and drug resistance (7,8). Whether anaesthetics 
are involved in tumour progression through the regulation of 
factors derived from fibroblasts remains to be clearly under‑
stood.
Rocuronium bromide (RB), vecuronium bromide (VB) and 
suxamethonium chloride CRS (SCC) are general intravenous 
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anaesthetics (9). Studies have demonstrated that RB and SCC 
could enhance gastric cancer and breast cancer cell prolifera‑
tion, invasion and migration and VB has been shown to promote 
the adhesiveness of gastric cancer cells (9,10). Additionally, 
dexmedetomidine hydrochloride (DH) was demonstrated to 
promote cancer cell proliferation and progression (11) whereas 
lidocaine, widely used as a local anaesthetic, has been demon‑
strated to reduce cancer recurrence and help cancer sensitivity 
to cisplatin (12,13).
In order to further explore the role of these anaesthetics 
in cancer progression and gain additional insights into their 
potential mechanisms, we explored whether different anaes‑
thetics may play a role in regulating SDF‑1 and HGF derived 
from fibroblasts.
Materials and methods
Cell culture. MRC‑5 cells were obtained from ATCC (LGC 
Standards). The cells were cultured in Dulbecco's modified 
Eagle's medium (DMEM) (Sigma‑Aldrich; Merck KGaA), 
supplemented with an antibiotic mixture containing peni‑
cillin, streptomycin and amphotericin B (Sigma‑Aldrich; 
Merck KGaA) and 10% foetal calf serum (FCS) 
(Sigma‑Aldrich), in an incubator at 37˚C, 95% humidification 
and 5% CO2.
Anaesthetics. The five anaesthetics RB, VB, SCC, DH and 
lidocaine are widely used in clinical practice. They were 
obtained from Sigma (Sigma‑Aldrich; Merck KGaA). RB, 
SCC and lidocaine were diluted in phosphate‑buffered 
saline (PBS), DH and VB were diluted in PBS containing 
dimethyl sulphoxide (DMSO) (Sigma‑Aldrich; Merck KGaA) 
to generate stocks. Final concentrations were based on 
extrapolation from anaesthetic doses used in clinical practice 
and from previous cell culture experiments where available. 
Subsequently, RB was diluted with DMEM to 8 µg/ml, 45 and 
80 µg/ml (10). VB was diluted with DMEM to 1.5 µg/ml, 10 and 
15 µg/ml (10). SCC was diluted with DMEM to 20 µg/ml, 
100 and 200 µg/ml (10). DH was diluted with DMEM to 
2.5 ng/ml, 5 and 50 ng/ml (11,14‑16). Lidocaine was diluted 
with DMEM to 0.1 mM, 1 and 10 Mm (12,13,17‑19). Control 
groups consisted of either media alone or media containing the 
respective final concentration of DMSO in accordance with 
treatment preparation.
Treatment of MRC‑5 cells with anaesthetics. MRC‑5 cells were 
seeded into 6‑well plates and cultured until 70‑90% confluent. 
Following this, MRC‑5 cells were treated with different 
concentrations of anaesthetics or control solutions. Following 
that the 6‑well plates were incubated at 37˚C for 1 h.
Total RNA isolation and RNA quantification. Following treat‑
ment of MRC‑5 with the respective anaesthetics, RNA was 
extracted using TRI reagent (Sigma‑Aldrich; Merck KGaA) 
in accordance with the manufacturer's instructions. Following 
extraction and resuspension, RNA concentration was measured 
using a nanophotometer (Implen, Geneflow).
Reverse Transcription (RT). RNA from MRC‑5 cells treated 
with different anaesthetics was standardised to 500 ng 
and used as a template for reverse transcription to generate 
cDNA using a GoScript oligo (dT) Reverse Transcription 
kit (Promega Corp.) in accordance with the manufacturer's 
instructions. The reaction was undertaken in a SimpliAmp 
Thermal Cycler (Thermo Fisher Scientific, Inc.).
Polymerase chain reaction (PCR) and agarose gel 
electrophoresis. PCR was performed on sample cDNA to 
probe for molecules of interest. The 16 µl reaction consisted of 
cDNA, forward primer, reverse primer (Table I), GoTaq Green 
Mastermix (Promega Corp.) and PCR grade water and was 
conducted in a SimpliAmp Thermal Cycler (Thermo Fisher 
Scientific, Inc.). Following this, DNA fragments were separated 
by agarose (Melford Laboratories Ltd.) gel electrophoresis.
Reverse transcription‑quantitative PCR (RT‑qPCR). The 
Amplifilour™ Uniprimer™ Universal system (Intergen 
Company) was used to quantify relative transcript copy 
number as previously described (20). In brief, the reaction 
contained a forward primer, reverse primer (Table I), present 
at 1/10th concentration of the forward primer and containing 
an additional sequence named as the Z sequence (5'‑ACT GAA 
CCT GAC CGT ACA‑3'), Uniprimer probe, 2X Precision FAST 
mastermix (Primerdesign), cDNA and PCR water. All samples 
were run alongside standards of known transcript copy 
numbers, allowing generation of a standard curve and deter‑
mination of relative transcript expression within each sample.
The reaction was undertaken in a StepOne Plus qPCR 
system (Thermo Fisher Scientific, Inc.). Additionally, sample 
glyceraldehyde 3‑phosphate dehydrogenase (GAPDH) levels 
were also quantified and used to normalise transcript expres‑
sion.
Statistical analysis. Statistical analysis was undertaken using 
a one‑way analysis of variance (ANOVA), with Holm‑Sidak 
post hoc analysis used to compare individual groups to the 
control, and the SigmaPlot (version 11) statistical software. 
Every experiment was repeated at least three times. Differences 
were considered statistically significant when P<0.05. Bar 
charts were prepared using GraphPad Prism (version 8) soft‑
ware.
Results
Effect of different anaesthetics on SDF‑1 transcript expression 
in MRC‑5 cells. The impact of anaesthetic treatment on MRC‑5 
transcript expression was examined using PCR. The results 
showed that the expression of SDF‑1 was generally reduced 
with increasing doses of RB (Fig. 1A), DH (Fig. 1B) and SCC 
(Fig. 1C). A slight increased SDF‑1 expression was observed 
with increasing doses of VB (Fig. 1D). Lidocaine had little 
effect on SDF‑1 expression in MRC‑5 cells (Fig. 1E).
SDF‑1 expression was further explored using qPCR. 
Expression in the treatment groups was calculated as a 
percentage of the control group, which itself was taken as 
having a value of 100%. Similar to the PCR result, the RB treat‑
ment group showed a reduced expression of SDF‑1 following 
treatment and this was found to be significant, with post hoc 
analysis indicating a significant reduction in the 45 µg/ml 
group compared with 0 µg/ml group (P<0.05) (Fig. 1F). Lower 
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expression of SDF‑1 was also observed following treatment 
with DH, apparent at the 2.5 and 50 ng/ml concentrations, 
though a large degree of variability was observed in the 
5 ng/ml group which limited statistical significance (Fig. 1G). 
Similarly, SCC generally decreased SDF‑1 expression over 
increasing concentrations, but this was variable and did not 
reach statistical significance (P>0.05; Fig. 1H). No significant 
difference in SDF‑1 expression was noted following treatment 
with VB (Fig. 1I). Lidocaine had variable effects, increasing 
SDF‑1 expression at the 0.1 and 1 mM concentration but 
brining about a large reduction at 10 mM, though ANOVA 
analysis indicated no significance within the group (Fig. 1J).
Table I. PCR and quantitative PCR primer sequences used to detect SDF‑1, HGF and GAPDH.










The Z sequences are presented in italics. SDF‑1, stromal cell‑derived factor‑1; HGF, hepatocyte growth factor.
Figure 1. Effect of anaesthetics on SDF‑1 transcript expression in MRC‑5 fibroblasts. SDF‑1 transcript expression was assessed using PCR following treatment 
with a range of concentrations of (A) RB, (B) DH, (C) SCC, (D) VB and (E) lidocaine. Representative images are shown. Additionally, SDF‑1 transcript 
expression was quantified using quantitative PCR following treatment with varying concentrations of (F) RB, (G) DH, (H) SCC, (I) VB and (J) lidocaine. 
Data are presented as the mean percentage control values +/‑ standard error of mean. Statistical comparisons were performed using ANOVA. *P<0.05 vs. 
0 µg/ml control. SDF‑1, stromal cell‑derived factor‑1; RB, rocuronium bromide; DH, dexmedetomidine hydrochloride; SCC, suxamethonium chloride CRS; 
VB, vecuronium bromide.
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Effect of different anaesthetics on HGF expression in MRC‑5 
cells. Conventional PCR analysis demonstrated reduced HGF 
transcript expression at the lower 20 and 100 µg/ml concentra‑
tions but no difference compared to the control at the 200 µg/ml 
treatment concentration of SCC treatment (Fig. 2A). However, 
VB, RB, DH and lidocaine treatment generally produced 
little or no change in HGF transcript levels in MRC‑5 cells 
(Fig. 2B‑E).
Similarly, qPCR analysis was also used to explore HGF 
transcript expression following treatment with the various 
anaesthetics. Expression in the treatment groups was calcu‑
lated as a percentage of the control group, which itself was 
taken as having a value of 100%. As with the PCR data, SCC 
treatments tended to decrease HGF expression at 20 and 
100 µg/ml but had no effect at the higher 200 µg/ml, 
although no statistical significance was observed (Fig. 2F). 
Interestingly, a slight enhancement of HGF expression was 
noted following the 15 µg/ml treatment of VB but ANOVA 
analysis demonstrated no significance within the group 
(Fig. 2G). No significant differences in HGF expression 
were identified following RB, DH or lidocaine treatment, 
with little variation in HGF expression from the controls 
observed following treatment of MRC‑5 cells with these 
anaesthetics (Fig. 2H‑J).
Discussion
Anaesthetics are unavoidable for patients undergoing major 
cancer surgery. In recent years increasing evidence indicates 
that anaesthetics may impact patients undergoing surgery 
for cancer resection, highlighting the potential effect of 
anaesthetics on cancers (21‑23). Some research has shown 
that anaesthetic drugs contribute to tumour proliferation 
and metastasis, whilst others have demonstrated the reverse 
response (1,3,10,17). The mechanisms by which anaesthetics 
influence tumour growth and dissemination remain poorly 
understood. Our study examined five different widely used 
anaesthetics and how they may impact the production of 
cancer promoting factors from stromal cells.
In order to explore our hypothesis, we focused on five 
intravenous and local anaesthetics, namely RB, VB, SCC, DH 
and lidocaine. RB, VB and SCC are anaesthetics which act 
by blocking nerve impulses to muscles. Previous research has 
demonstrated that RB can enhance gastric cancer growth, inva‑
sion and migration and promote MDA‑MB‑231 breast cancer 
cell proliferation, migration and invasion (9,10). Similarly, 
SCC has also been found to promote MDA‑MB‑231 prolif‑
eration, migration and invasion (10). VB has been noted to 
influence the malignant phenotype of cancer cells at a common 
Figure 2. Effect of Anaesthetics on HGF transcript expression in MRC‑5 fibroblasts. HGF transcript expression was assessed using PCR following treatment 
with a range of concentrations of (A) SCC, (B) VB, (C) RB, (D) DH and (E) lidocaine. Representative images are shown. HGF transcript expression was also 
quantified using quantitative PCR following treatment with varying concentrations of (F) SCC, (G) VB, (H) RB, (I) DH and (J) lidocaine. Data are presented 
as the mean percentage control values +/‑ standard error of mean. Statistical comparison were performed using ANOVA. HGF, hepatocyte growth factor; 
RB, rocuronium bromide; DH, dexmedetomidine hydrochloride; SCC, suxamethonium chloride CRS; VB, vecuronium bromide.
ONCOLOGY LETTERS  21:  140,  2021 5
concentration, whilst it has been observed to have an impact 
at a higher dose in gastric cancer but had very little impact 
on MDA‑MB‑231 breast cancer cells (9,10). DH is a highly 
selective α2‑adrenergic receptor agonist (1). α2‑adrenergic 
receptors have been shown to be expressed by human breast 
cancer cells (24) and DH has been shown to promote tumour 
growth and metastasis in murine mammary tumours (25). It 
was also demonstrated to increase cell proliferation, migration 
and survival by activating α2‑adrenoceptors in lung carci‑
noma (16). Lidocaine acts by blocking voltage‑gated sodium 
channels (VGSC) on the nerve cell membrane. Several studies 
have demonstrated that lidocaine can inhibit growth, invasion, 
metastasis and promote apoptosis in lung adenocarcinoma 
cells, breast cancer and hepatocellular cancer cells (19,26,27).
Until now, a number of mechanisms have been implicated 
in relation to how other anaesthetic drugs can impact on 
the tumour process. For instance, it has been demonstrated 
that propofol can inhibit the migratory capacity of cervical 
cancer cells by altering their morphology by regulating 
cytoskeletal structural stability and affecting the membrane 
ultrastructure (28). Additionally, it has also been indicated to 
induce apoptosis and inhibit growth and migration by influ‑
encing a number of different pathways. In colorectal cancer 
cells propofol was shown to influence the phosphatidylino‑
sitol 3‑kinase (PI3K)/protein kinase B (AKT) pathway and in 
pancreatic cancer cells it was found to regulate miR‑21/Slug 
signals, where Slug has been implicated as a zinc finger tran‑
scriptional repressor known to promote cancer cell invasion 
and survival (29). Morphine has been shown to prompt breast 
cancer cell migration by inducing overexpression of neuro‑
epithelial cell transforming 1 (NET1) which is important in 
cell migration (30). Local anaesthetics such as lidocaine and 
ropivacaine have been suggested to induce non‑small cell lung 
cancer (NSCLC) cell apoptosis, to be involved in apoptotic 
pathways and mitogen activated protein kinase (MAPK) path‑
ways and to inhibit cell growth by arresting cell cycles at G0/1 
phase through downregulating cyclin D1 which plays a vital 
role in G1 to S phase progression (17).
It appears that anaesthetics can influence cancer activity, 
not only via cancer cells directly but also via an indirect 
impact. It is known that surgical tumour resection can some‑
times induce tumour recurrence and metastasis. One of the 
reasons is that surgery can inhibit the immune system and also 
affects the inflammatory system (1). Propofol has been proven 
to protect the immune system from being suppressed (31,32). 
Hence, this may represent one method through which 
propofol could inhibit cancer growth and migration. Cell 
experiments and retrospective studies have suggested that 
DH engages in promoting tumour activity and is associated 
with reduced inflammatory cytokine release and regulation 
of the immune system (33). For example, DH could promote 
tumour metastasis and angiogenesis by expanding monocytic 
myeloid‑derived suppressor cells (MDSC), and monocytic 
MDSC have the capacity to inhibit T cell proliferation and 
produce the proangiogenic factor vascular endothelial growth 
factor (VEGF) (11). Thereby, cancer progression is influenced 
not only by tumour cells themselves but also the contributions 
of components in the TME. Taken together, a full under‑
standing of the mechanism of anaesthetics in cancer is crucial 
for selecting an effective treatment.
The TME is key in influencing the development and 
dissemination of cancer. It consists of the ECM, cytokines 
and stromal cells including fibroblasts, endothelial cells and 
immune cells (34). Fibroblasts, as the key members of the 
stroma, play a crucial role in tumour‑stroma interaction (7). 
Cancer associated fibroblasts (CAF) can release a number 
of growth factors, cytokines, chemokines and other stimuli, 
most of which promote tumour progression, though some 
inhibit tumour function (35,36). SDF‑1 known as chemokine 
(C‑X‑C motif) ligand 12 (CXCL12) is a chemokine secreted 
by fibroblasts and engages in tumourigenesis and metastatic 
activity in different types of cancers, such as breast cancer (37), 
colorectal cancer (38) and lung cancer (39). The chemokine 
(C‑X‑C motif) receptor 4 (CXCR4), a SDF‑1 receptor, has been 
found to be overexpressed in over 30 types of tumours (8). Its 
role in promoting tumour growth, migration and angiogenesis 
is achieved via the CXCL12/CXCR4 axis (8). HGF, released 
by tumour and fibroblasts, is a key cytokine that binds its 
receptor c‑MET on different tumour cells. It modulates 
tumour processes such as proliferation, motility, angiogenesis, 
invasion and metastasis through the HGF/c‑MET signalling 
pathway (40). Both are key factors derived from fibroblasts and 
contribute to tumour progression in the TME. In the current 
study we explored how the expression of these key factors in 
fibroblasts could be influenced after treatment with anaesthetic 
drugs.
Previous in vitro studies showed that RB promoted breast 
cancer and gastric cancer cell proliferation, migration and inva‑
sion (9,10). SCC also increased the breast cancer cells' malignant 
phenotype but this was not seen in gastric cancer (10). VB had 
little impact on gastric and breast cancer cells activity (9,10). 
In vitro experiments have suggested that DH contributed to 
cell proliferation and metastasis. Similar results were reported 
in vivo, which showed that DH also participated in the promo‑
tion of tumour growth (41,42). Several studies proved that 
lidocaine could inhibit tumour cell proliferation, invasion and 
migration (19,26,27). In our research, we explored the effect of 
RB, VB, SCC, DH and lidocaine on the production of SDF‑1 
and HGF in MRC‑5 cells. SDF‑1 was significantly reduced by 
RB treatment at a concentration of 45 µg/ml. The DH treatment 
group also showed lower SDF‑1 transcript levels at concentra‑
tions of 2.5 and 50 ng/ml, although there was a large degree of 
variability in the 5 ng/ml DH treatment group. SCC treatment 
resulted in a similar trend to RB treatment, although it did not 
reach statistical significance. SCC and VB treatment appear to 
have similar trends on HGF expression. It seemed that HGF 
transcript expression was reduced at the lower 20 and 100 µg/ml 
concentrations of SCC treatment but little impact on expression 
was seen at the 200 µg/ml SCC concentration compared to the 
control group. VB treatment also appeared to decrease HGF 
expression at 1.5 and 10 µg/ml concentrations but no effect 
at the higher 15 µg/ml concentration. Our study showed that 
lidocaine resulted in a large reduction of SDF‑1 expression at 
10 mM concentration but had little impact at the other concen‑
trations and no impact on HGF expression in MRC‑5 fibroblast 
cells. Previous studies proved that RB, SCC and DH act in a 
promotive role for tumour growth, invasion and migration and 
lidocaine is an inhibitor of tumour progression. However, our 
current work demonstrates that some anaesthetics may inhibit 
SDF‑1 and HGF expression to some extent in MRC‑5 and hence 
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could subsequently impact tumour proliferation, migration 
and angiogenesis in response to such factors. Previous studies 
explored the impact of the anaesthetics directly on cancer cells, 
whereas here our work has focused on the implications on the 
stromal components. It is likely that both aspects are key in the 
overall response of the tumour to such anaesthetics. Multiple 
factors should be taken into consideration when exploring the 
impact of anaesthetics on the tumour process. Therefore, addi‑
tional complex, co‑culture and in vivo assessment is needed to 
further understand the full significance.
There are, however, limitations to our research. Firstly, 
we used only one type of fibroblast cell, MRC‑5, which may 
not be representative of all fibroblasts in vivo. Secondly, the 
impact of the various anaesthetics on the expression of SDF‑1 
and HGF were investigated at the transcript level in this initial 
study. Whilst this raises an important relationship of signifi‑
cant importance, both HGF and SDF‑1 are secreted proteins. 
Therefore, the findings reported in this manuscript represent 
preliminary data. It is now of fundamental importance to further 
examine this relationship at the protein level and, importantly, 
in the context of the impact on secretion and bioactivity of such 
factors in the microenvironment, to validate these initial find‑
ings. This warrants further biochemical investigation to fully 
establish the impact of anaesthetics on fibroblast‑cancer cell 
signalling. Thirdly, our model lacks a combination of tumour 
cells and TME to more fully inform the study. Additional 
research is required to investigate the impact of conditioned 
fibroblast derived medium, following anaesthetic exposure, 
on cancer cells. Furthermore, the current study investigated 
only one chemokine and one cytokine which makes it harder 
to represent the TME completely. Ultimately, animal studies 
and prospective randomized controlled trials will be required. 
It will be important not only to study individual drug effects on 
cancer growth and progression markers, but also to look at drug 
combinations, dosing schedules and exposure times in order to 
elucidate the optimum anaesthetic regimens for patients under‑
going major cancer surgery in the future.
In conclusion, this study has shown that some anaesthetic 
drugs have the capacity to inhibit SDF‑1 and HGF expression 
to some extent in MRC‑5 fibroblasts. This alone may not result 
in inhibition of tumour proliferation and metastasis but does 
provide insights into the impact of anaesthetics on fibroblasts 
derived factors which may provide a new direction for improving 
cancer treatment. However, in vitro research cannot truly reflect 
the complex interaction between drugs and multiple cell types 
in vivo. Further studies are required to confirm the exact role of 
different anaesthetic agents in promoting or suppressing cancer 
cell proliferation and dissemination. This may open up a novel 
way in which cancer surgery could be optimised in future to 
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